ArticleDiscover oncology2025
Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study was designed to investigate the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109.
methodsWe employed the TCGA and GTEx databases to analyze the expression levels of c-Met and PD-L1 in esophageal cancer tissues. Immunohistochemistry was employed to detect the expression of c-Met and PD-L1 in clinical esophageal cancer tissues and adjacent normal tissues. Flow cytometry was employed to verify the expression of c-Met and PD-L1 in ECA109 cells. T cells from healthy volunteers were extracted and activated, and c-Met/PD-1 CAR-T cells were prepared utilizing lentivirus. Flow cytometry was employed to detect the positive rate, subtype, antibody secretion, and anti-apoptotic effects of c-Met/PD-1 CAR-T cells. The experimental group consisted of c-Met/PD-1 CAR-T cells, with c-Met CAR-T and CD19 CAR-T as control groups, and Active T cells as the blank control group. The proliferation, cytokine secretion, and killing ability of CAR-T cells co-cultured with ECA109 cells were assessed utilizing cell viability assays (CCK-8), enzyme-linked immunosorbent assays (ELISA), and lactate dehydrogenase release assays (LDH). In vivo experiments were conducted by subcutaneously injecting ECA109 cells into nude mice to establish tumor-bearing models. CAR-T cells were administered via in situ injection, and changes in body weight and tumor volume were measured. Hematoxylin and eosin (HE) staining was performed on heart, liver, spleen, lung, and kidney tissues from sacrificed mice.
resultsc-Met and PD-L1 were highly expressed in esophageal cancer tissues but were low or not expressed in adjacent normal tissues. ECA109 cells expressed c-Met and PD-L1 on their surface. Successfully prepared c-Met/PD-1 CAR-T cells secreted PD-1 antibodies that blocked PD-1 on the surface of CAR-T cells. Under stimulation by c-Met antigens, c-Met/PD-1 CAR-T cells exhibited stronger proliferation, cytokine release, and killing ability. In vivo experiments demonstrated significant tumor inhibition in nude mice treated with c-Met/PD-1 CAR-T cells without evident off-target effects.
conclusionThe c-Met/PD-1 CAR-T cells were successfully constructed and demonstrated significant in vitro and in vivo killing effects on ECA109 esophageal cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.